-
Taxonomy & unit
-
ratio: %
-
Description
-
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q3 2024.
- Inhibikase Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 73.7 %, a 377% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)